Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ibuprofen 5% spray
1003020P0AAADAD
|
Ibuprofen (Topical Antirheumatic) | Ibuprofen | Musculoskeletal and Joint Diseases | 5,647 |
|
Voltarol Osteoarthritis Joint Pain Relief 1.16% gel
1003020AFBBABAA
|
Voltarol Emulgel | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 5,357 |
|
Methylprednisolone 80mg / Lidocaine 20mg/2ml (1%) inj vials
1001022K0AAAFAF
|
Methylprednisolone acetate | Methylprednisolone acetate | Musculoskeletal and Joint Diseases | 5,162 |
|
Nabumetone 500mg tablets
1001010X0AAAAAA
|
Nabumetone | Nabumetone | Musculoskeletal and Joint Diseases | 5,100 |
|
Metoject PEN 17.5mg/0.35ml inj pre-filled pens
1001030U0BEAQBV
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 4,908 |
|
Diclofenac sodium 25mg gastro-resistant tablets
1001010C0AAADAD
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 4,686 |
|
Diclofenac sodium 75mg gast res MR caps
1001010C0AAARAR
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 4,591 |
|
Hydroxychloroquine 300mg tablets
1001030C0AABMBM
|
Hydroxychloroquine sulfate | Hydroxychloroquine sulfate | Musculoskeletal and Joint Diseases | 4,418 |
|
Methotrexate 20mg/0.4ml inj pre-filled disposable devices
1001030U0AABWBW
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 4,326 |
|
Metoject PEN 12.5mg/0.25ml inj pre-filled pens
1001030U0BEAYCD
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 4,123 |
|
Robaxin 750 tablets
1002020S0BBAAAB
|
Robaxin | Methocarbamol | Musculoskeletal and Joint Diseases | 4,109 |
|
Phorpain Maximum Strength 10% gel
1003020P0BMAAAI
|
Phorpain (Topical) | Ibuprofen | Musculoskeletal and Joint Diseases | 4,059 |
|
Ibuprofen 100mg/5ml oral suspension
1001010J0AAACAC
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 3,983 |
|
Mefenamic acid 250mg tablets
1001010N0AAAJAJ
|
Mefenamic acid | Mefenamic acid | Musculoskeletal and Joint Diseases | 3,914 |
|
Methotrexate 10mg tablets
1001030U0AAACAC
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 3,448 |
|
Ibuprofen 200mg/5ml oral suspension sugar free
1001010J0AABRBR
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 3,264 |
|
Methotrexate 15mg/0.3ml inj pre-filled disposable devices
1001030U0AACCCC
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 3,057 |
|
Methylprednisolone acetate 80mg/2ml inj vials
1001022K0AAABAB
|
Methylprednisolone acetate | Methylprednisolone acetate | Musculoskeletal and Joint Diseases | 2,976 |
|
Metoject PEN 22.5mg/0.45ml inj pre-filled pens
1001030U0BEASBX
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 2,976 |
|
Methotrexate 25mg/0.5ml inj pre-filled disposable devices
1001030U0AACBCB
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 2,776 |
|
Salicylic acid 2% / Mucopolysaccharide polysulfate 0.2% crm
1003020W0AAABAB
|
Heparinoid (Topical Antirheumatic) | Heparinoid | Musculoskeletal and Joint Diseases | 2,647 |
|
Ibugel 5% gel
1003020P0BDAAAC
|
Ibugel | Ibuprofen | Musculoskeletal and Joint Diseases | 2,579 |
|
Ibuprofen 5% / Levomenthol 3% gel
1003020P0AAAHAH
|
Ibuprofen (Topical Antirheumatic) | Ibuprofen | Musculoskeletal and Joint Diseases | 2,529 |
|
Metoject PEN 7.5mg/0.15ml inj pre-filled pens
1001030U0BEATBY
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 2,476 |
|
Ibuprofen 400mg capsules
1001010J0AAAUAU
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 2,392 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.